

Original

Plasma total homocysteine in Brazilian overweight and non-overweight adolescents: a case-control study

R. S. Brasileiro*, M. A. M. S. Escrivão*, J. A. A. C. Taddei*, V. D'Almeida**, F. Ancona-Lopez* and J. T. A. Carvalhaes***

From the Department of Pediatrics. Federal University of São Paulo. Brazil.

*Discipline of Nutrition and Metabolism. **Discipline of Genetics. ***Discipline of Pediatric Specialties.

Rosana S. Brasileiro was supported by a grant from CAPES (a Brazilian Research Foundation).

Abstract

Objective: To test the hypothesis that overweight adolescents have higher plasma total homocysteine (tHcy) levels than non-overweight adolescents and to explore the association between plasma tHcy levels with folate, vitamin B₁₂ and some risk factors for CVD in both groups.

Methods: A case-control study conducted with 239 adolescents aged 15-19 years in the city of São Paulo, Brazil; 86 overweight and 153 non-overweight frequency matched by age, gender, pubertal and socioeconomic status. tHcy, folate, vitamin B₁₂, lipid profile, glucose, insulin and insulin resistance were measured.

Results: No significant differences were found in tHcy, folate and vitamin B₁₂ levels between overweight and non-overweight groups. The geometric means of tHcy were elevated in both groups (overweight: 11.8 µmol/L; non-overweight: 11.6 µmol/L) higher for boys than for girls ($P \leq 0.001$). Folate deficiency was identified in 68.6% of total studied population. Triacylglycerol, LDL cholesterol, insulin resistance were higher and HDL cholesterol was lower in overweight than non-overweight adolescents. In the multiple linear regression model, in overweight group, tHcy was independently associated with age ($P = 0.041$), sex ($P = 0.004$) and folate ($P = 0.022$) and in non-overweight group, with age ($P = 0.049$), sex ($P < 0.001$), folate ($P = 0.018$) and vitamin B₁₂ ($P = 0.030$).

Conclusions: Obesity was not a determinant factor of tHcy levels. Age, sex and folate were independent determinants of plasma tHcy levels. The high prevalence of

HOMOCISTEÍNA PLASMÁTICA TOTAL EN ADOLESCENTES BRASILEÑOS CON Y SIN SOBREPESO: UN ESTUDIO DE CASOS-CONTROL

Resumen

Objetivo: Probar la hipótesis de que los adolescentes con sobrepeso tienen mayores concentraciones plasmáticas de homocisteína total (tHcy) que los adolescentes sin sobrepeso, y explorar la asociación entre las concentraciones plasmáticas de tHcy con folato, vitamina B₁₂ y algunos factores de riesgo de ECV en ambos grupos.

Métodos: Estudio de casos-control realizado en 239 adolescentes de edades entre los 15-19 años, de la ciudad de Sao Paulo, Brasil; 86 tenían sobrepeso y 153 no, emparejados por edad, sexo, estado puberal y socioeconómico. Se midieron tHcy, folato, vitamina B₁₂, perfil lipídico, glucosa, insulina y resistencia a insulina.

Resultados: no se hallaron diferencias significativas en las concentraciones de tHcy, folato ni vitamina B₁₂ entre los grupos con y sin sobrepeso. Las medias geométricas de tHcy estaban elevadas en ambos grupos (sobrepeso: 11,8 µmol/l; sin sobrepeso: 11,6 µmol/l), y fueron mayores en los chicos que las chicas ($P \leq 0,001$). Se identificó la deficiencia de folatos en el 68,6% de la población total estudiada. El triacilglicerol, el colesterol-LDL y la resistencia a insulina fueron mayores en el grupo de adolescentes con sobrepeso, y el colesterol-HDL fue superior en el grupo sin sobrepeso. En el modelo de regresión lineal múltiple, en el grupo con sobrepeso, la tHcy se asoció, de forma independiente, con la edad ($P = 0,041$), el sexo ($P = 0,004$) y el folato ($P = 0,022$) y, en el grupo sin sobrepeso, con la edad ($P = 0,049$), el sexo ($P < 0,001$), el folato ($P = 0,018$) y la vitamina B₁₂ ($P = 0,030$).

Conclusiones: la obesidad no fue un factor determinante de las concentraciones de tHcy. La edad, el sexo y el folato fueron determinantes independientes de las concentraciones plasmáticas de tHcy. La prevalencia elevada de deficiencia de folato podría haber sido responsable de las concentraciones elevadas de tHcy en estos adoles-

Correspondencia: J. A. A. C. Taddei
Disciplina de Nutrologia. Departamento de Pediatria
UNIFESP - Universidade Federal de São Paulo
R. Loefgreen 1647, São Paulo
SP 04040-032 Brasil
E-mail: taddei.dped@epm.br / nutsec@yahoo.com.br

Recibido: 7-II-2005.
Aceptado: 12-IV-2005.

folate deficiency may have been responsible for the elevated tHcy levels in these adolescents, increasing the risk for future development of CVD.

(*Nutr Hosp* 2005, 20:313-319)

Key words: *Homocysteine. Folate. Vitamin B₁₂. Obesity. Adolescence. Insulin resistance. Lipid profile.*

Introduction

The prevalence of overweight and obesity in children and adolescents is increasing rapidly in developed countries as well as in developing countries.¹ In Brazil, as in United States and Europe, an increase in the prevalence of obesity strictly related to changes in lifestyle and eating habits has been observed². Analyses from the National Health and Nutrition Examination Surveys (1963-1991) demonstrated a continuous rise in the prevalence of overweight adolescents from 15% to 22%³.

Overweight children and adolescents present several risk factors for future cardiovascular diseases⁴. There is a clear association between childhood obesity and adult cardiovascular mortality⁵. In Brazil, cardiovascular disease is the foremost cause of death and it is estimated that the prevention of overweight and obesity could reduce the incidence of cardiovascular disease by at least 30%⁶.

Obesity may be associated with increased plasma tHcy levels in adults^{7,8}. Some studies with children and adolescents observed a positive association between tHcy levels and body mass index^{9,10}. In obese children and adolescents, tHcy levels were strongly related with body mass index and insulin, suggesting that hyperinsulinism associated to obesity may contribute to impairment of homocysteine metabolism¹¹.

Homocysteine is a sulfhydryl-containing amino acid derived from the metabolic demethylation of dietary methionine. There are two pathways in the homocysteine metabolism: remethylation and transsulfuration. Folate, vitamin B₁₂ and vitamin B₆ are essential cofactors in these pathways¹². Plasma tHcy levels are controlled by interplay of genetic and nutritional factors. Individuals with a nutritional deficiency that leads to low blood levels of folate, vitamin B₁₂ or vitamin B₆ are at risk of hyperhomocysteinemia¹³.

McCully and Wilson¹⁴ proposed the homocysteine theory of atherosclerosis based upon pathological examinations of autopsy material from children with hyperhomocysteinuria¹⁵. This observation led to the hypothesis that homocysteine may contribute to the development of atherosclerosis. Results from about 80 clinical and epidemiological studies have shown that even a moderate elevation of tHcy levels can be associated with an increased risk of cardiovascular disease¹⁶.

Obese adolescents present a high risk for developing dyslipidemias, hyperinsulinism and insulin resis-

centes, aumentando el riesgo de desarrollo futuro de ECV.

(*Nutr Hosp* 2005, 20:313-319)

Palabras clave: *Homocisteína. Folato. Vitamina B₁₂. Obesidad. Adolescencia. Resistencia a la insulina. Perfil lipídico.*

tance. A few studies have investigated plasma tHcy levels in overweight adolescents. Determining tHcy, folate, vitamin B₁₂, lipid profile, insulin resistance and their relations with overweight and obesity in adolescence is relevant for the adoption of preventive measures with the objective of correcting deficiencies, improving quality of life, reducing risk of chronic diseases, especially cardiovascular diseases, and consequently increasing life expectancy. Thus, our purpose was to test the hypothesis that overweight adolescents have higher plasma tHcy levels than non-overweight adolescents and to explore the association between plasma tHcy concentration with folate, vitamin B₁₂, lipid profile, glucose, insulin and insulin resistance in both groups.

Subjects and methods

The case-control study was carried out in the city of Sao Paulo, state of Sao Paulo, Southeastern Brazil, from August to December 2002. For allocation into overweight and non-overweight groups, a team of trained nutritionists and pediatricians weighed and measured 1,420 adolescents born between January 01, 1982 and December 31, 1987, representing 98.68% of all students enrolled in one public high-school of São Paulo. Sixteen (1.11%) youngsters refused to be evaluated and three (0.21%) were not found after at least three attempts. The adolescents were measured during their physical education classes and body mass indexes (BMI) were calculated as weight (Kg)/height² (m). Of the 263 eligible adolescents, participants in every phase of the study, 9.12% (n = 24) were excluded (4 - hypothyroidism; 6 - blood sample hemolysis; 8 - vitamin supplementation; and 6 - use of medication that could alter the tHcy results). The sample then comprised 239 adolescents; 86 identified as overweight (BMI ≥ 85th) and 153 as non-overweight (5th ≤ BMI < 85th)¹⁷ frequency matched by age, sex, socioeconomic status and pubertal stage 4 or 5 according to Tanner¹⁸. Data on birth, personal history (e.g., history of chronic diseases), familial cardiovascular disease (coronary artery disease, stroke, or peripheral vascular disease in the family, including parents, grandparents, uncles and aunts) and use of medication were collected using a standardized and pre-tested questionnaire applied by trained nutritionists and pediatricians to both overweight and non-overweight adolescents. Adolescents suffering from severe illness with clinical and laboratorial confirmation of the diagnosis

(e.g., renal, heart, respiratory, hepatic, endocrine or neurological disease) and those taking medication regularly, except for oral contraceptives in girls (5 overweight and 9 non-overweight), were excluded from the study. The study was approved by the Ethics Committee of the Federal University of São Paulo. Written, informed consent was obtained from each adolescent and their parents before the study started.

Biochemical Analysis

Blood samples were collected by peripheral venous puncture, in the morning, after a 12-hour fast, in order to determine tHcy, folate, vitamin B₁₂, HDL cholesterol, LDL cholesterol, triacylglycerol, glucose and insulin levels. Blood samples for the measurement of tHcy were collected in tubes containing EDTA. Plasma was isolated by centrifugation (3,000 X g at 4°C for 20 min) and immediately stored at -80° for two months until analyzed. The plasma tHcy levels were measured by high performance liquid chromatography (HPLC)¹⁹. Hyperhomocysteinemia was defined as a tHcy concentration > 15 µmol/L²⁰. Serum levels of folate were measured using Ion Capture Technology (AxSYM System-ABBOTT Laboratories, Illinois, USA) and vitamin B₁₂ were measured by MEIA-Microparticle Enzyme Immunoassay Technology (AxSYM System-ABBOTT Laboratories, Illinois, USA). The normality range considered for serum folic acid was 5.0-16.0 ng/mL and for vitamin B₁₂ was 200-1,000 pg/ml. HDL cholesterol and triacylglycerol levels were measured by using colorimetric method (VITROS SYSTEMS CHEMISTRY 750 XRC-Ortho-Clinical Diagnostics, Inc-Johnson & Johnson Company, New York-USA). LDL cholesterol levels were calculated with the Friedewald formula when triacylglycerol was lower than 400 mg/dl²¹. Glucose was detected by enzymatic method utilizing hexokinase and glucose-6-phosphate dihydrogenase enzymes (Advia Chemistry System 1650-Bayer). Insulin was measured by two-site immunoassay (TOSOH-TOSOH CORPORATION, Tokyo, Japan). The insulin resistance was determined by homeostasis model assessment for insulin resistance (HOMA-IR), calculating the product of the fasting plasma insulin (µU/mL) and fasting plasma glucose (mmol/L) divided by 22.5²².

Statistical Analysis

The continuous variables that were not normally distributed according to Shapiro-Wilk test were log₁₀ transformed (tHcy, folate, vitamin B₁₂, HDL cholesterol, LDL cholesterol, triacylglycerol, insulin and HOMA-IR) and their values were presented as geometric mean and 95% confidence interval. The continuous variables normally distributed were expressed as mean and standard deviation. Comparisons between overweight and non-overweight groups and between males and females were assessed by Student's *t*-test.

Correlations between the tHcy and all other continuous variables were calculated using Pearson's correlation coefficient in overweight and non-overweight groups. In order to observe the association between tHcy and all studied variables (age, sex, folate, vitamin B₁₂, HDL cholesterol, LDL cholesterol, triacylglycerol, glucose, insulin and HOMA-IR) a simple linear regression model was used and the significant variables (*P* < 0.05) were included in the multiple linear regression model. Statistical tests were considered significant when *P* < 0.05. The statistical analyses were completed using the software Stata 8.0 (Stata Corp., College Station, TX, USA).

Results

The clinical and biochemical characteristics of the overweight and non-overweight adolescents are described in table I. Some data are expressed as mean and standard deviation and others as geometric mean and 95% confidence interval.

Plasma tHcy levels were high in both overweight and non-overweight groups. According to Student's *t*-test there was no significant difference in tHcy levels between the overweight and non-overweight groups even when distributed according to sex. Elevated levels of tHcy appeared in both groups independently of

Table I
*Characteristics clinical and biochemical in overweight and non-overweight adolescents**

	Overweight <i>n</i> = 86	Non-overweight <i>n</i> = 153	<i>P</i>
Sex (M/F)	41/45	70/83	
Age [†] (Years)	16.0 ± 1.0	16.3 ± 1.0	0.079
BMI [†]	29.6 ± 2.9	20.4 ± 2.1	<0.001
tHcy [‡] (µmol/L)			
All	11.8 (10.9-12.8)	11.6 (11.0-12.2)	0.696
Male	13.5 (11.9-15.4) [§]	13.1 (12.1-14.2) [¶]	0.662
Female	10.4 (9.5-11.4)	10.4 (9.8-11.1)	0.968
Folate [‡] (ng/mL)	4.3 (3.9-4.7)	4.1 (3.9-4.4)	0.495
Vitamin B ₁₂ [‡] (pg/mL)	411.0 (373.5-452.2)	451.5 (422.0-483.1)	0.106
HDL cholesterol [‡] (mg/dL)	43.5 (41.2-45.8)	50.2 (48.2-52.3)	<0.001
LDL cholesterol [‡] (mg/dL)	98.4 (93.3-103.8)	90.6 (86.9-94.5)	0.018
Triacylglycerol [‡] (mg/dL)	90.3 (81.3-100.2)	73.3 (69.5-77.3)	<0.001
Glucose [‡] (mg/dL)	83.6 (± 6.4)	82.3 (± 6.4)	0.138
Insulin [‡] (µU/mL)	11.7 (10.3-13.1)	6.4 (5.9-6.8)	<0.001
HOMA-IR [‡]	2.4 (2.1-2.7)	1.3 (1.2-1.4)	<0.001

* Means or geometric means of the overweight and non-overweight adolescents were compared by Student's *t*-test.

[†] Mean ± SD.

[‡] Geometric mean; 95% CIs in parentheses.

[§] Significant sex difference: §*P* = 0.001; ¶*P* ≤ 0.001 (Student's *t*-test). BMI, body mass index; tHcy, total homocysteine; HDL-c, high-density lipoprotein; LDL, low density lipoprotein. HOMA-IR, Homeostasis model assessment for insulin resistance. Fasting plasma insulin (µU/mL) x fasting plasma glucose (mmol/L)/22.5.




Fig. 1.—Association between plasma tHcy levels and folic acid in overweight adolescents $n = 86$ (A) and non-overweight adolescents $n = 153$ (B).

the nutritional condition. We observed hyperhomocysteinemia ($> 15 \mu\text{mol/L}$) in 46 adolescents (19.2%) from the total sample. In both groups, plasma tHcy levels exhibited higher mean values in males than in females ($P \leq 0.001$).

Likewise, there was no significant difference between overweight and non-overweight adolescents in relation to folate and vitamin B₁₂ levels. Considering the adolescents as a whole, the deficiencies of folate and vitamin B₁₂ were identified in 68.6% ($n = 164$) and 2.5% ($n = 6$), respectively.

Overweight adolescents presented geometric means significantly higher for LDL cholesterol, triacylglycerol, insulin and HOMA-IR than non-overweight adolescents. The HDL cholesterol geometric mean was lower in overweight than in non-overweight individuals. There was no significant difference in the glucose mean between the groups.

Applying Pearson correlation coefficient with tHcy as dependent variable and the clinical and laboratorial variables as independent, we observed a negative co-

Table II
Variables associated with plasma tHcy levels in overweight adolescents*

	β coefficient	95% CI	P
Age (Years)	0.032	(0.001; 0.063)	0.041
Sex [†]	-0.095	(-0.159; -0.031)	0.004
Folate	-0.219	(-0.406; -0.032)	0.022
Vitamin B ₁₂	-0.090	(-0.255; 0.074)	0.278

* Values for plasma tHcy levels, folate and vitamin B₁₂, were log₁₀-transformed before analysis. β coefficients and P values were determined by multiple linear regression analyses and adjusted for all variables listed. β coefficients are the log₁₀ of tHcy per unit change in the independent variable (age, folate and vitamin B₁₂).

[†] Females in relation to males.

$n = 86$.

relation with folate ($r = -0.2928$, $P = 0.0062$) and positive with age ($r = 0.2534$, $P = 0.0186$) in the overweight group. In the non-overweight group there was a negative correlation with folate ($r = -0.1798$, $P = 0.0262$) and vitamin B₁₂ ($r = -0.1959$, $P = 0.0152$) and a positive correlation with age ($r = 0.1599$, $P = 0.0483$). There was no correlation between tHcy and HDL cholesterol, LDL cholesterol, triacylglycerol, glucose, insulin and HOMA-IR in either the overweight or non-overweight groups.

The association between tHcy and folate in overweight and non-overweight adolescents obtained in the linear regression model is shown in figure 1.

The multiple linear regression model showed that tHcy in the overweight group remained independently associated with age, sex and folate and that in the non-overweight group the tHcy remained independently associated with age, sex, folate and vitamin B₁₂ (tables II and III).

Discussion

Our results showed that there was no significant difference in plasma tHcy levels between overweight

Table III
Variables associated with plasma tHcy levels in non-overweight adolescents*

	β coefficient	95% CI	P
Age (Years)	0.021	(0.000; 0.042)	0.049
Sex [†]	-0.089	(-0.132; -0.047)	< 0.001
Folate	-0.156	(-0.286; -0.026)	0.018
Vitamin B ₁₂	-0.127	(-0.243; 0.012)	0.030

* Values for plasma tHcy levels, folate and vitamin B₁₂, were log₁₀-transformed before analysis. β coefficients and P values were determined by multiple linear regression analyses and adjusted for all variables listed. β coefficients are the log₁₀ of tHcy per unit change in the independent variable (age, folate and vitamin B₁₂).

[†] Females in relation to males.

$n = 153$.

and non-overweight adolescents. Similarly, other studies with children and adults have not found an association between tHcy and BMI²³⁻²⁵. On the other hand, Tungtrongchitr and cols.⁷ observed higher plasma tHcy levels in the overweight group of adults when compared with non-overweight group, although the case group also presented lower serum folate levels when compared to the control group.

Apart from nutritional condition, the results of tHcy levels in this study presented high values when compared to other studies with adolescents in the same age range. Four studies that assessed plasma tHcy levels in adolescents found lower values than our study. De Laet and cols.²³ observed a geometric mean of 9.78 $\mu\text{mol/L}$ in boys and 8.33 $\mu\text{mol/L}$ in girls, aged 15-19 years. The tHcy levels assessed by National Health and Nutrition Examination Survey (NHANES III), based on a sample of 295 boys and 345 girls aged 16-19 years, found geometric mean values of 8.7 $\mu\text{mol/L}$ for boys and 7.2 $\mu\text{mol/L}$ for girls combining race and ethnic groups²⁶. In Bogalusa Heart Study²⁷, a geometric mean of 6.3 $\mu\text{mol/L}$ (5.9-6.7 $\mu\text{mol/L}$) was verified in individuals aged 15-17 years. Bates and cols.²⁴, found geometric mean of 8.5 $\mu\text{mol/L}$ for boys and 7.8 $\mu\text{mol/L}$ for girls aged 15-18 years.

Another factor to be considered refers to the prevalence of hyperhomocysteinemia in the studied population. Hyperhomocysteinemia (tHcy > 15 $\mu\text{mol/L}$) was detected in 18.6% (n = 16) overweight adolescents and 19.6% (n = 30) non-overweight adolescents. A normal plasma tHcy concentration is approximately 10 $\mu\text{mol/L}$, varying from 5 to 15 $\mu\text{mol/L}$. Values above 15 $\mu\text{mol/L}$ are considered to be hyperhomocysteinemia²⁰. The prevalence of hyperhomocysteinemia is estimated at 5% in general population and 13-47% among patients with symptoms of atherosclerotic vascular diseases¹⁵. Hyperhomocysteinemia has been recognized as an important independent risk factor for cardiovascular disease^{28, 29}. McCully³⁰, states that the ideal plasma concentration of this aminoacid should be below 10 $\mu\text{mol/L}$. In patients with coronary artery disease, Nygard and cols.³¹ estimated that the mortality ratio for an increase of 5 $\mu\text{mol/L}$ in the tHcy concentration was 1.6 between 10 and 15 $\mu\text{mol/L}$ and 2.5 between 15 and 20 $\mu\text{mol/L}$. Results of meta-analysis, concluded that a 5 $\mu\text{mol/L}$ tHcy increment elevates CVD risk by as much as cholesterol increases of 20 mg/dL²⁹.

In our study we observed differences in tHcy levels between sexes, as these were higher in boys than in girls, in both overweight and non-overweight groups. This fact could be due to age > 15 years. Studies state that in non-pubertal children the tHcy levels are similar³² and that after puberty, the levels are higher in boys than in girls^{10, 23, 24, 27, 33}. Men present higher tHcy levels than women, possibly due to stoichiometric formation of homocysteine in connection with creatine/creatinine synthesis that is proportional to muscular mass, generally bigger in men¹⁵. Another hy-

pothesis perhaps is the hormonal protection in women³⁴. These differences were also observed when the multiple linear regression model was applied.

Regarding age, this study demonstrated that despite the little range of age, the plasma tHcy levels increased with age in both groups, a finding also reported by other studies on adolescents aged over 15 years^{23, 32}.

We measured two cofactors involved in tHcy metabolism, folate and vitamin B₁₂. Serum folate and vitamin B₁₂ levels did not differ in overweight and non-overweight adolescents. There was a negative correlation between tHcy and folate in both overweight and non-overweight groups. There was a negative correlation of vitamin B₁₂ with tHcy just in the non-overweight group. When the determinant factors of tHcy levels were analyzed applying the multiple linear regression model, we observed a significant negative association between tHcy and folate in overweight and non-overweight groups. Several other studies have demonstrated an inverse association between tHcy and folate^{10, 13, 35}. In children, tHcy was more closely correlated with folate and less with vitamin B₁₂^{10, 23}. We observed that 66.3% (n = 57) of overweight and 69.9% (n = 105) of non-overweight adolescents, presented folate deficiency with serum values < 5.0 ng/mL. The high tHcy levels in the studied population might have been due to the great deficiency of folate we found. The increase of plasma tHcy levels is also considered a sensitive marker of folate and vitamin B₁₂ deficiency^{28, 36}. Selhub and cols.¹³ state that 2/3 of all cases of elevated tHcy levels are attributed to low levels of these vitamins. Other authors have identified plasma tHcy concentration significantly increased in individuals with low levels of folate and vitamin B₁₂^{8, 37}. There is a good correlation between serum folate and vitamin B₁₂ levels with their food intake³⁸ since serum levels are totally dependent on this food intake. It must be emphasized that this population did not eat any food fortified with folate. The supplementation with these vitamins or food fortification easily reduces the plasma tHcy levels^{39, 40}. Several countries have already opted for food fortification with folate initially to reduce the risk of neural tube defects. In the United States and Canada, such food fortification with folate started at the end of the 90's^{41, 42}. The introduction of fortification with folate in U.S. has reduced the prevalence of hyperhomocysteinemia⁴³. In Brazil, the legislation on food fortification with folate was recently approved but to-date has not been thoroughly implemented⁴⁴.

We found significantly higher insulin levels and insulin resistance measured by HOMA-IR in overweight compared to non-overweight adolescents. Overweight individuals tend towards greater insulin resistance than non-overweight. Insulin resistance and hyperinsulinemia have been demonstrated in obese adolescents^{45, 46}. However, when we assessed the relation between tHcy and insulin resistance we did not find any association, corroborating the findings of ot-

her studies⁴⁷⁻⁴⁹. On the other hand, Gallistl and cols.¹¹ reported an association between tHcy and plasma insulin in obese children and adolescents. However, in that study plasma insulin was also inversely related with plasma folate suggesting a subclinical deficiency in obese children¹¹.

Concluding our study, obesity did not influence the elevated tHcy levels, which were more associated with deficiency of folate. High tHcy levels may increase the risk for future development of CVD in this population, indicating the importance of preventive measures and educational programs regarding alimentary habits and lifestyle. Genetic factors could also be further studied to identify other causes that may contribute to elevated tHcy levels.

Acknowledgments

We thank Karolina Felcar Saraiva for advice on statistical analysis and the adolescents and their families for making this study possible.

This study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo-FAPESP (The State of São Paulo Research Foundation) Process number 03/00415-4.

References

- World Health Organization: *Obesity: preventing and managing the global epidemic*. Report of the WHO Consultation on Obesity. WHO, Geneva, 1998.
- Wang Y, Monteiro C, Popkin BM: Trends of obesity and underweight in older children and adolescents in the United States, Brazil, China, and Russia. *Am J Clin Nutr* 2002; 75: 971-7.
- Troiano RP, Flegal KM, Kuczmarski RJ, Campbell SM, Johnson CL: Overweight prevalence and trends for children and adolescents: the National Health and Nutrition Examination Surveys 1963 to 1991. *Arch Pediatr Adolesc Med* 1995; 149: 1085-91.
- Freedman DS, Dietz WH, Srinivasan SR, Berenson GS: The relation of overweight to cardiovascular risk factors among children and adolescents: The Bogalusa Heart Study. *Pediatrics* 1999; 103: 1175-82.
- Gunnell DJ, Frankel SJ, Nanchahal K, Peters TJ, Davey SG: Childhood obesity and adult cardiovascular mortality: a 57-y follow-up study on the Boyd Orr cohort. *Am J Clin Nutr* 1998; 67: 1111-8.
- Ministério da Saúde: *Plano nacional para a promoção da alimentação adequada e do peso saudável*. Ministério da Saúde, Brasília, DF, 1999.
- Tungtrongchitr R, Pongpaew P, Tongboonchoo C and cols.: Serum homocysteine, B12 and folic acid levels in Thai overweight and obese subjects. *Int J Vitam Nutr Res* 2003; 73: 8-14.
- Jacques PF, Bostom AG, Wilson PWF and cols.: Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. *Am J Clin Nutr* 2001; 73: 613-21.
- Shen MH, Chu NF, Wu DM, Chang JB: Plasma homocysteine, folate and vitamin B₁₂ levels among school children in Taiwan: The Taipei Children Heart Study. *Clinical Biochemistry* 2002; 35: 495-8.
- Osganian SK, Stampfer MJ, Spiegelman D and cols.: Distribution of and factors associated with serum homocysteine levels in children: child and adolescent trial for cardiovascular health. *JAMA* 1999; 281: 1189-96.
- Gallistl S, Sudi K, Mangge H, Erwa W, Borkenstein M: Insulin is an independent correlate of plasma homocysteine levels in obese children and adolescents. *Diabetes Care* 2000; 23: 1348-52.
- Hankey GJ, Eikelboom JW: Homocysteine and vascular disease. *Lancet* 1999; 354: 407-13.
- Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH: Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. *JAMA* 1993; 270: 2693-8.
- McCully KS, Wilson RB: Homocysteine theory of arteriosclerosis. *Atherosclerosis* 1975; 22: 215-27.
- McCully KS: Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. *Am J Pathol* 1969; 56: 111-28.
- Refsum H, Ueland PM, Nygard O, Vollset SE: Homocysteine and cardiovascular disease. *Annu Rev Med* 1998; 49: 31-62.
- Must A, Dallal GE, Dietz WH: Reference data for obesity: 85th and 95th percentiles of body mass index (wt/ht²) - a correction. *Am J Clin Nutr* 1991; 54: 773.
- Tanner JM: *Growth at adolescence*. 2nd ed. Blackwell Scientific Publications, Oxford, UK, 1962.
- Pfeiffer CM, Huff DL, Gunter EW: Rapid and accurate HPLC assay for plasma total homocysteine and cysteine in a clinical laboratory setting. *Clin Chem* 1999; 45: 290-2.
- Ueland PM, Refsum H, Stabler SP and cols.: Total homocysteine in plasma or serum: methods and clinical applications. *Clin Chem* 1993; 39: 1764-79.
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
- Matthews DR, Hosker JP, Rudenski AS and cols.: Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin levels in man. *Diabetologia* 1985; 28: 412-19.
- de Laet C, Wautrecht JC, Brasseur D and cols.: Plasma homocysteine levels in a Belgian school-age population. *Am J Clin Nutr* 1999; 69: 968-72.
- Bates CJ, Mansoor MA, Gregory J, Pentiev K, Prentice A: Correlates of plasma homocysteine, cysteine and cysteinyl-glycine in respondents in the British National Diet and Nutrition Survey of young people aged 4-18 years, and a comparison with the survey of people aged 65 years and over. *Br J Nutr* 2002; 87: 71-9.
- Fonseca VA, Fink LM, Kern PA: Insulin sensitivity and plasma homocysteine levels in non-diabetic obese and normal weight subjects. *Atherosclerosis* 2003; 167: 105-9.
- Must A, Jacques PF, Rogers G, Rosenberg IH, Selhub J: Serum total homocysteine levels in children and adolescents: results from the third National Health and Nutrition Examination Survey (NHANES III). *J Nutr* 2003; 133: 2643-9.
- Greenlund KJ, Srinivasan SR, Xu JH and cols.: Plasma homocysteine distribution and its association with parental history of coronary artery disease in black and white children: the Bogalusa Heart Study. *Circulation* 1999; 99: 2144-9.
- Nygard O, Vollset SE, Refsum H and cols.: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. *JAMA* 1995; 274: 1526-33.
- Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. *JAMA* 1995; 274: 1049-57.
- McCully KS: Homocysteine and vascular disease. *Nat Med* 1996; 56: 111-28.
- Nygard O, Nordrehaug JE, Refsum H and cols.: Plasma homocysteine levels and mortality in patients with coronary artery disease. *N Engl J Med* 1997; 337: 230-6.
- van Beynum IM, Smeitink JA, den Heijer M, te Poele Pothoff MT, Bolm HJ: Hyperhomocysteinemia: a risk factor for stroke in children. *Circulation* 1999; 99: 2070-2.
- Jacques PF, Rosenberg IH, Rogers G and cols.: Serum total homocysteine levels in adolescent and adult Americans: results from the third National Health and Nutrition Examination Survey. *Am J Clin Nutr* 1999; 69: 482-9.
- Morris MS, Jacques PF, Selhub J, Rosenberg IH: Total homocysteine and estrogen status indicators in the Third Natio-

- nal Health and Nutrition Examination Survey. *Am J Epidemiol* 2000; 15: 140-8.
35. Ubbink JB: Vitamin nutrition status and homocysteine: an atherogenic risk factor. *Nutr Rev* 1994; 52: 383-7.
 36. Savage DG, Lindenbaum J, Stabler SP, Allen RH: Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiencies. *Am J Med* 1994; 96: 239-46.
 37. Nygard O, Refsum H, Ueland PM, Vollset SE: Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study. *Am J Clin Nutr* 1998; 67: 263-70.
 38. Jacques PF, Sulsky SI, Sadowski JA and cols.: Comparison of micronutrient intake measured by a dietary questionnaire and biochemical indicators of micronutrient status. *Am J Clin Nutr* 1993; 57: 182-9.
 39. Jacques PF, Selhub J, Bostom AG, Wilson PWF, Rosenberg IH: The effect of folic acid fortification on plasma folate and total homocysteine levels. *N Engl J Med* 1999; 340: 1449-54.
 40. Malinow MR, Duell PB, Hess DL and cols.: Reduction of plasma homocysteine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. *N Engl J Med* 1998; 338: 1009-15.
 41. Oakley GP: Delaying folic acid fortification of flour. *BMJ* 2002; 324: 1348-9.
 42. Ray JG, Vermeulen MJ, Boss SC, Cole DE: Increased red cell folate levels in women of reproductive age after Canadian folic acid food fortification. *Epidemiology* 2002; 13: 238-40.
 43. Selhub J, Jacques PF, Bostom AG, Wilson PWF, Rosenberg IH: Relationship between plasma homocysteine and vitamin status in the Framingham study population: impact of folic acid fortification. *Public Health Rev* 2000; 28: 117-45.
 44. Agência Nacional de Vigilância Sanitária: *Regulamento técnico para fortificação das farinhas de trigo e das farinhas de milho com ferro e ácido fólico*. Resolução Anvisa RDC n.º 344, 13 dezembro 2002. Internet: <http://www.anvisa.gov.br/alimentos/farinha.htm> (accessed 23 August 2004).
 45. Weiss R, Dziura J, Burgert TS and cols.: Obesity and the metabolic syndrome in children and adolescents. *N Engl J Med* 2004; 350: 2362-74.
 46. Caprio S, Bronson M, Sherwin RS, Rife F, Tamborlane WV: Co-existence of severe insulin resistance and hyperinsulinaemia in pre-adolescent obese children. *Diabetologia* 1996; 39: 1489-97.
 47. Gillum RF: Distribution of serum homocysteine and its association with parental history and cardiovascular risk factors at ages 12-16 years: the Third National Health and Nutrition Examination Survey. *Ann Epidemiol* 2004; 14: 229-33.
 48. Abbasi F, Facchini F, Humphreys MH, Reaven GM: Plasma homocysteine levels in healthy volunteers are not related to differences in insulin-mediated glucose disposal. *Atherosclerosis* 1999; 146: 175-8.
 49. Godsland IF, Rosankiewicz JR, Proudler AJ, Johnston DG: Plasma total homocysteine levels are unrelated to insulin sensitivity and components of the Metabolic Syndrome in healthy men. *J Clin Endocrinol Metab* 2001; 86: 719-23.